{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-050889","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.372864+00:00","generated_at":"2026-06-03T03:43:58.262659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amarin Q1 revenue $56.5M (-34% YoY); European in-market sales +65% QoQ; GAAP loss $0.02","bullets":["U.S. net product revenue fell 41% YoY to $48.1M on generic price erosion; gross margin narrowed to 55% from adjusted 70% a year ago.","GAAP net loss $10.0M ($0.02/share) vs loss $16.5M ($0.04) Q1'23; non-GAAP adjusted net loss $4.7M ($0.01) vs income $7.6M ($0.02) YoY.","European in-market sales grew ~65% Q1'24 vs Q4'23, driven by Spain (+91% patients on therapy) and UK (+28%).","EPO issued new VAZKEPA patent extending IP protection in Europe until 2039; $50M share repurchase program approved, pending UK High Court OK in Q2.","Cash & investments $308.2M, stable over seven quarters; on track for $40M annual cost savings from July 2023 restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-050889","json":"https://secwatch.observer/filing/0000950170-24-050889.json","markdown":"https://secwatch.observer/filing/0000950170-24-050889.md","text":"https://secwatch.observer/filing/0000950170-24-050889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/0000950170-24-050889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/amrn-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:43:58.262659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34e5b332fc36c5441bc195b5fbcf329a5529bb58","claim":"AMARIN CORP PLCUK reported the three months ended March 31, 2024 results: revenue $56.5 million.","evidence_excerpt":"Total net revenue for the three months ended March 31, 2024 was $56.5 million, compared to $86.0 million in the corresponding period of 2023, a decrease of 34%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/0000950170-24-050889-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$56.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}